Anne Marie Handrup Kverneland

Novo Nordisk Ltd. engages in the sale and marketing of pharmaceutical products for the treatment of chronic conditions in the United Kingdom. It offers medicines for the treatment of diabetes, and hemophilia and bleeding disorders, as well as for growth hormone therapy and hormone replacement therapy. The company is headquartered in Crawley, the United Kingdom.

Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark.